Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione Italiana Sclerosi Multipla
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Group A (MS)
* Age 18-55 years;
* Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;
* Course of the disease: RR-SP-PP-CIS;
* Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;
* Not in clinical relapse (at least 30 days after the last clinical relapse);
* Subjects treated or non-treated with immunomodulatory and immunosuppressive drugs;
* Signature of the informed consent.
Group B (HC)
Age 18-55 years;
Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);
Signature of the informed consent.
The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres.
Group C (OND)
Aged 18-55 years;
Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.
Group D (ONDi)
Age 18-55 years;
subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;
Signature of the informed consent.
You may not be if
• The presence of acute or chronic disease which are disabling or interfere with the design and objective of the study;
* Clinically proven cardiopathy (NYHA ≥ I class);
* Previous episodes of venal thromboembolism (including either deep venal thrombosis or pulmonary embolism);
* Neoplasms;
* Thrombophilia from an anamnestic definition;
* Diabetes;
* Primary or secondary pulmonary hypertension and in treatment for it;
* Concurrent systemic steroid treatments or in the last 30 days;
